Pharmaceutical company Innocoll Holdings Limited said on Thursday that it has re-filed its New Drug Application (NDA) with the US Food and Drug Administration (FDA) for XARACOLL.
The investigational agent XARACOLL (bupivacaine hydrochloride collagen-matrix implants) is being reviewed for the management of postsurgical pain after open inguinal hernia surgery.
The FDA has set a PDUFA goal date of 26 August 2020.
XARACOLL is a late-stage bioresorbable collagen-matrix surgical implant that is being developed by Innocoll for the management of postsurgical pain relief through the delivery of bupivacaine, a local anaesthetic, at the surgical site.
If approved by the FDA, XARACOLL will be Innocoll's first commercially available product in the United States.
AbbVie's ELAHERE receives full US FDA approval
Johnson & Johnson's OPSYNVI receives US FDA approval
Outlook Therapeutics receives positive CHMP opinion for ONS-5010 in wet AMD treatment
Human Immunology Biosciences receives ODD from FDA for felzartamab
Eton Pharmaceuticals acquires PKU GOLIKE, expanding rare disease portfolio
Vertex receives FDA clearance for VX-407 Investigational New Drug Application for ADPKD
Phanes Therapeutics receives FDA Fast Track designation for PT886
Bio-Thera Solutions signs new licensing agreement with SteinCares
FDA accepts resubmission of Citius Pharmaceuticals, Inc's BLA for LYMPHIR
GSK Plc reports positive Phase III Jemperli data for endometrial cancer
ImmVira receives FDA Fast Track designation for MVR-T3011 IT